Douglas Evans biography
Douglas G. Evans serves as Independent Chairman of the Board of the Company. has been a member of our Board since April 2020. Mr. Evans has served as the President and Chief Executive Officer of Lungpacer Medical Inc., a medical device company, since January 2014. Prior to joining Lungpacer, Mr. Evans served as the Chief Operating Officer and a member of the board of directors of Kensey Nash Corporation, a medical device company, from March 1995 to June 2013. Mr. Evans currently serves on the board of directors of Intact Vascular, a medical device company. Mr. Evans holds a Master of Science degree in Electrical Engineering and Photonics from the University of Pennsylvania, a M.B.A. from Pennsylvania State University Great Valley School of Graduate Professional Studies and a Bachelor’s of Science in Engineering Sciences from the Pennsylvania State University Skills & Qualifications: Mr. Evans’ extensive executive leadership experience, deep knowledge of the medical device field and his experience with the commercialization of medical products provide him with the qualifications and skills to serve on our Board.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Douglas Evans?
Douglas Evans is 56, he's been the Independent Chairman of the Board of TELA Bio since 2020. There are 5 older and 10 younger executives at TELA Bio. The oldest executive at TELA Bio, Inc. is Maarten Persenaire, 63, who is the Co-Founder, Chief Medical Officer.
What's Douglas Evans's mailing address?
Douglas's mailing address filed with the SEC is C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA, 19355.
Insiders trading at TELA Bio
Over the last 5 years, insiders at TELA Bio have traded over $4,222,376 worth of TELA Bio stock and bought 4,343,227 units worth $46,898,981 . The most active insiders traders include Management Inc. Opaleye, Investments, Lpwong Roderic... és Advisors Llc Orbi Med Capit.... On average, TELA Bio executives and independent directors trade stock every 18 days with the average trade being worth of $139,070. The most recent stock trade was executed by Advisors Llc Orbi Med Capit... on 28 June 2024, trading 428,300 units of TELA stock currently worth $2,021,576.
What does TELA Bio do?
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
What does TELA Bio's logo look like?
TELA Bio executives and stock owners
TELA Bio executives and other stock owners filed with the SEC include:
-
Antony Koblish,
President, Chief Executive Officer, Co-Founder, Director -
Maarten Persenaire,
Co-Founder, Chief Medical Officer -
Ellis Greenhalgh,
Chief Technology Officer -
Antony Koblish,
Co-founder, Pres, CEO & Director -
Dr. E. Skott Greenhalgh Ph.D.,
Chief Technology Officer -
kurt Azarbarzin,
Independent Director -
Vince Burgess,
Independent Director -
Federica OBrien,
Independent Director -
Adele Oliva,
Independent Director -
Lisa Colleran,
Independent Director -
Peter Murphy,
Chief Commercial Officer -
Nora Brennan,
Chief Financial Officer -
Douglas Evans,
Independent Chairman of the Board -
D. Taylor Ocasio,
Gen. Counsel -
Francis Michael Conway,
VP of Fin., Treasurer & Assistant Sec. -
Peter C. Murphy,
Chief Commercial Officer -
Paul Talmo,
Chief Strategic Officer -
Michael Leonard,
Sr. VP of Operations, Quality & Regulatory -
Jennifer Lou Armstrong,
Sr. VP of HR -
Christopher H. Smith,
Sr. VP of Sales -
Megan Smeykal,
VP, Corp. Controller, Chief Accounting Officer & Principal Accounting Officer -
Roberto E. Cuca J.D.,
CFO & COO -
Bio Ventures Ii Lp Quaker B...,
-
Ronald J. Jr.Pacira Bio Sci...,
-
Ashley Friedman,
Director -
Investments, Lpwong Roderic...,
-
Matt Zuga,
Director -
Federica F. O'brien,
Director -
Advisors Llc Orbi Med Capit...,
-
Healthcare Partners Fund 2,...,
-
John Nosenzo,
Director -
Roberto Cuca,
COO and CFO -
Megan Smeykal,
Chief Accounting Officer -
Paul Talmo,
Chief Technology Officer -
Management Inc. Opaleye,
-
Jeffrey Blizard,
Director -
Gregory A. Firestone,
Chief Commercial Officer